Cytokine Signalling Forum

CME Courses




« Return to Overview

Highlights from EULAR 2018: Current and Future Perspectives in the Cytokine Signalling Blockade

Developed by CESAS Medical, under the auspices of the University of Glasgow This activity is supported by unrestricted educational grants from Pfizer Italia S.R.L. and Lilly

Release date: 30 July 2018
Estimated time to complete activity: 1 hour, 15 minutes
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
  • Be familiar with the latest clinical data on marketed cytokine signalling agents in rheumatoid arthritis from EULAR 2018
  • Be aware of new indications where cytokine signalling agents are being evaluated
  • Have learnt about novel insights and new agents in clinical development

TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with rheumatic disease.

PROGRAMME OVERVIEW
EULAR 2018 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included those relating to marketed cytokine signalling agents and newer agents in cytokine signalling.

In this activity, Highlights from EULAR 2018: Current and Future Perspectives in the Cytokine Signalling Blockade, a panel of international experts discuss key abstracts and data from EULAR 2018, specifically relating to cytokine signalling science.

JAK inhibitors are now being marketed for the treatment of rheumatoid arthritis, and new data are showing how these agents perform in clinical practice. It is also exciting to see on how these agents could be used in the clinic for other indications beyond rheumatoid arthritis. There is, therefore, an educational need to keep up-to-date with ongoing research to understand the impact of these latest data on both current and future clinical practice.

In addition, with the considerable data continuing to be published on JAK inhibition, not only with Phase 2/3 data of newer JAK inhibitors, but also with basic science data providing novel insights into cytokine signalling, it is of increasing importance to stay abreast of the latest information that is available, since applying this knowledge may make a difference to patients in the clinic.

This course, Highlights from EULAR 2018: Current and Future Perspectives in the Cytokine Signalling Blockade outlines recent developments in cytokine signalling science, and highlights the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

Please note that this course is currently awaiting accreditation.

View congress highlights


You are using an out of date browser. Please upgrade your browser to have access to the modules below.



Module Presenter Video Questions
Introduction
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
02:14
Clinical Data on Marketed Cytokine Signaling Agents in Rheumatoid Arthritis
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
Professor Kurt de Vlam image
Professor Kurt de Vlam

Professor and Principal Investigator ,
University Hospitals Leuven, Belgium; 4th Military Medical University Xi'an, China

Kurt de Vlam is a Principal Investigator in Rheumatology at the University Hospitals Leuven, Belgium.

Professor de Vlam obtained his medical degree, rheumatology specialization, and PhD from Ghent University, Belgium. He then joined University Hospitals Leuven, where he is currently the group leader for spondyloarthropathies and psoriatic arthritis, responsible for a specialized outpatient clinic for spondyloarthropathies and psoriatic arthritis. Professor de Vlam is also a visiting Professor at the 4th Military Medical University Xi’an, in Xi’an, China.

As well as conducting clinical trials, Professor de Vlam is the founder of the spondyloarthritis registries SPAR and BIOSPAR, databases at the Rheumatology Department of the University Hospitals Leuven. He is also a Principal Investigator for the BEPASS cohort, a longitudinal observational cohort in psoriatic arthritis in Belgium. Professor de Vlam’s research interest include biomechanics, pathological bone formation, rare bone and joint diseases, eHealth applications, as well as the development and implementation of early phase and late phase clinical trials.

Prof. Kurt de Vlam (Bio)
15:30 5
New Indications for Cytokine Signaling Agents - Psoriatic Arthritis and Beyond
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
Professor Thomas Huizinga image
Professor Thomas Huizinga

Director and Professor of Medicine,
Leiden University Medical Center, Lieden, Netherlands

Thomas Huizinga is Professor of Rheumatology, Department Head of Rheumatology, and Vice-clinical Educator of Rheumatology at Leiden University Medical Center, Leiden, Netherlands. He is also Chairman of the ‘Meteor’ foundation, an international registry of rheumatoid arthritis disease activity and medication use in more than 20 countries, and is also Chairman of the National Postgraduate Educational Committee of Dutch Rheumatology.

Professor Huizinga completed medical school and his doctorate research at the University of Amsterdam. He subsequently studied at Dartmouth Medical School, New Hampshire, US, and then specialised as a rheumatologist at Leiden University Medical Center, where he became a full Professor of Rheumatology in 2000.

For more than 30 years, Professor Huizinga has carried out research on pathogenesis, diagnostics and treatment of rheumatological disorders. He has published more than 750 scientific publications and more than 20 book chapters. He has also served on the editorial boards of many journals including Plos Medicine, Annals of Rheumatic Diseases, and Arthritis Rheumatism.

Professor Huizinga has participated in a number of international scientific committees, including those that established the 2010 ACR-EULAR criteria for RA, and the EULAR guidelines for the treatment of rheumatoid arthritis. He has been awarded with a number of prizes including in 1997 the EULAR young investigator award, in 2009 the ‘Willy van Heuman award for generation of in vitro models as alternatives for animal models’, and in 2011 the ‘Eurolife Distinguished Faculty Lecture Medal’ by the Karolinska Institut in Stockholm, Sweden.

Prof. Thomas Huizinga (Bio)
20:13 4
Novel Insights and New Agents in Cytokine Signalling
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
Professor Thomas Huizinga image
Professor Thomas Huizinga

Director and Professor of Medicine,
Leiden University Medical Center, Lieden, Netherlands

Thomas Huizinga is Professor of Rheumatology, Department Head of Rheumatology, and Vice-clinical Educator of Rheumatology at Leiden University Medical Center, Leiden, Netherlands. He is also Chairman of the ‘Meteor’ foundation, an international registry of rheumatoid arthritis disease activity and medication use in more than 20 countries, and is also Chairman of the National Postgraduate Educational Committee of Dutch Rheumatology.

Professor Huizinga completed medical school and his doctorate research at the University of Amsterdam. He subsequently studied at Dartmouth Medical School, New Hampshire, US, and then specialised as a rheumatologist at Leiden University Medical Center, where he became a full Professor of Rheumatology in 2000.

For more than 30 years, Professor Huizinga has carried out research on pathogenesis, diagnostics and treatment of rheumatological disorders. He has published more than 750 scientific publications and more than 20 book chapters. He has also served on the editorial boards of many journals including Plos Medicine, Annals of Rheumatic Diseases, and Arthritis Rheumatism.

Professor Huizinga has participated in a number of international scientific committees, including those that established the 2010 ACR-EULAR criteria for RA, and the EULAR guidelines for the treatment of rheumatoid arthritis. He has been awarded with a number of prizes including in 1997 the EULAR young investigator award, in 2009 the ‘Willy van Heuman award for generation of in vitro models as alternatives for animal models’, and in 2011 the ‘Eurolife Distinguished Faculty Lecture Medal’ by the Karolinska Institut in Stockholm, Sweden.

Prof. Thomas Huizinga (Bio)
Professor Kurt de Vlam image
Professor Kurt de Vlam

Professor and Principal Investigator ,
University Hospitals Leuven, Belgium; 4th Military Medical University Xi'an, China

Kurt de Vlam is a Principal Investigator in Rheumatology at the University Hospitals Leuven, Belgium.

Professor de Vlam obtained his medical degree, rheumatology specialization, and PhD from Ghent University, Belgium. He then joined University Hospitals Leuven, where he is currently the group leader for spondyloarthropathies and psoriatic arthritis, responsible for a specialized outpatient clinic for spondyloarthropathies and psoriatic arthritis. Professor de Vlam is also a visiting Professor at the 4th Military Medical University Xi’an, in Xi’an, China.

As well as conducting clinical trials, Professor de Vlam is the founder of the spondyloarthritis registries SPAR and BIOSPAR, databases at the Rheumatology Department of the University Hospitals Leuven. He is also a Principal Investigator for the BEPASS cohort, a longitudinal observational cohort in psoriatic arthritis in Belgium. Professor de Vlam’s research interest include biomechanics, pathological bone formation, rare bone and joint diseases, eHealth applications, as well as the development and implementation of early phase and late phase clinical trials.

Prof. Kurt de Vlam (Bio)
27:48 7
Close
Professor Philip Mease image
Professor Philip Mease

Director and Professor of Medicine,
University of Washington School of Medicine, Swedish Medical Center in Seattle, Washington, USA

Philip Mease is a Clinical Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Center in Seattle, Washington, US. His clinical practice is based at Seattle Rheumatology Associates.

Dr Mease obtained his undergraduate and medical degrees at Stanford University Medical School, and he completed his residency in internal medicine at the University of Washington’s School of Medicine, where he also served as Chief Resident and Fellow in Rheumatology.

As well as conducting clinical trials on emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis, and lupus, he also conducts research in disease state metrics and is the Co-chair of three working groups for OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia, and single-joint assessment. Dr Mease is also a member of the Soluble Biomarker working group.

Dr Mease is a founding organiser and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group). He has published 18 book chapters and nearly 400 journal articles, and serves as a reviewer for many journals including Arthritis & Rheumatism, Arthritis Care & Research, Annals of the Rheumatic Diseases, and Journal of Rheumatology. Dr Mease has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Prof. Philip Mease (Bio)
00:57
Evaluation 17

Date of preparation: 20 July 2018